Percentage of smudge cells determined on routine blood smears is a novel prognostic factor in chronic lymphocytic leukemia

Leukemia Research

Volumn 34, Issue 7, 2010, Pages 892-898

  Johansson, P ^a   Eisele, L ^a   Klein Hitpass, L ^a   Sellmann, L ^a   Duhrsen U ^a   Durig J ^a   Nuckel H ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

B cell chronic lymphocytic leukemia (B CLL); CD38 antigen; Protein tyrosine kinase ZAP 70; Smudge cells; TRIB2; Vimentin

Indexed keywords

CD38 ANTIGEN; PROTEIN KINASE ZAP 70;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BLOOD SAMPLING; BLOOD SMEAR; CANCER GROWTH; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CHRONIC LYMPHATIC LEUKEMIA; CORRELATION ANALYSIS; CYTOGENETICS; DISEASE MARKER; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN CELL; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SMUDGE CELL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD38; B-LYMPHOCYTES; CELL DEATH; CHROMOSOME ABERRATIONS; DIAGNOSTIC TESTS, ROUTINE; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE COUNT; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; VIMENTIN; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 77952957320     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.02.038     Document Type: Article

References (28)

1. Chiorazzi N., Rai K.R., Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005, 352(8):804-815.
2. Shanafelt T.D., Geyer S.M., Kay N.E. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004, 103(4):1202-1210.
3. Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94(6):1840-1847.
4. Dürig J., Naschar M., Schmücker U., Renzing-Kohler K., Holter T., Hüttmann A., et al. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 2002, 16(1):30-35.
5. Dürig J., Nückel H., Cremer M., Fuhrer A., Halfmeyer K., Fandrey J., et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 2003, 17(12):2426-2434.
6. Kay N.E., O'Brien S.M., Pettitt A.R., Stilgenbauer S. The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. Leukemia 2007, 21(9):1885-1891.
7. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., Stevenson F.K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94(6):1848-1854.
8. Nowakowski G.S., Hoyer J.D., Shanafelt T.D., Geyer S.M., LaPlant B.R., Call T.G., et al. Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test. Mayo Clin Proc 2007, 82(4):449-453.
9. Nowakowski G.S., Hoyer J.D., Shanafelt T.D., Zent C.S., Call T.G., Bone N.D., et al. Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia. J Clin Oncol 2009, 27(11):1844-1849.
10. Deaglio S., Capobianco A., Bergui L., Durig J., Morabito F., Duhrsen U., et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 2003, 102(6):2146-2155.
11. Schroers R., Griesinger F., Trumper L., Haase D., Kulle B., Klein-Hitpass L., et al. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 2005, 19(5):750-758.
12. Hüttmann A., Klein-Hitpass L., Thomale J., Deenen R., Carpinteiro A., Nückel H., et al. Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status. Leukemia 2006, 20(10):1774-1782.
13. Argiropoulos B., Palmqvist L., Yung E., Kuchenbauer F., Heuser M., Sly L.M., et al. Linkage of Meis1 leukemogenic activity to multiple downstream effectors including Trib2 and Ccl3. Exp Hematol 2008, 36(7):845-859.
14. Keeshan K., Shestova O., Ussin L., Pear W.S. Tribbles homolog 2 (Trib2) and HoxA9 cooperate to accelerate acute myelogenous leukemia. Blood Cells Mol Dis 2008, 40(1):119-121.
15. Stirewalt D.L., Meshinchi S., Kopecky K.J., Fan W., Pogosova-Agadjanyan E.L., Engel J.H., et al. Identification of genes with abnormal expression changes in acute myeloid leukemia. Genes Chromosomes Cancer 2008, 47(1):8-20.
16. Keeshan K., He Y., Wouters B.J., Shestova O., Xu L., Sai H., et al. Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia. Cancer Cell 2006, 10(5):401-411.
17. Cheson B.D., Bennett J.M., Grever M., Kay N., Keating M.J., O'Brien S., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996, 87(12):4990-4997.
18. Sellmann L., Gesk S., Walter C., Ritgen M., Harder L., Martin-Subero J.I., et al. Trisomy 19 is associated with trisomy 12 and mutated IGHV genes in B-chronic lymphocytic leukaemia. Br J Haematol 2007, 138(2):217-220.
19. Irizarry R.A., Hobbs B., Collin F., Beazer-Barclay Y.D., Antonellis K.J., Scherf U., et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4(2):249-264.
20. Tusher V.G., Tibshirani R., Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001, 98(9):5116-5121.
21. Storey J.D., Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003, 100(16):9440-9445.
22. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998, 95(25):14863-14868.
23. Nowakowski G., Lee Y., Bone N. Proteomic analysis of chronic lymphocytic leukemia cells identifies vimentin as a novel prognostic factor for aggressive disease. Blood 2005, 106:209.
24. Caligaris-Cappio F., Bergui L., Tesio L., Corbascio G., Tousco F., Marchisio P.C. Cytoskeleton organization is aberrantly rearranged in the cells of B chronic lymphocytic leukemia and hairy cell leukemia. Blood 1986, 67(1):233-239.
25. Stark R.S., Liebes L.F., Shelanski M.L., Silber R. Anomalous function of vimentin in chronic lymphocytic leukemia lymphocytes. Blood 1984, 63(2):415-420.
26. Krober A., Seiler T., Benner A., Bullinger L., Bruckle E., Lichter P., et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002, 100(4):1410-1416.
27. Brown M.J., Hallam J.A., Colucci-Guyon E., Shaw S. Rigidity of circulating lymphocytes is primarily conferred by vimentin intermediate filaments. J Immunol 2001, 166(11):6640-6646.
28. Schmitt-Graff A., Chaponnier C., Gabbiani G. Cytoskeletal organization of peripheral blood normal and leukemic lymphocytes and lymphoblasts. J Submicrosc Cytol 1987, 19(2):329-335.